Advertisement

AAPS PharmSciTech

, Volume 16, Issue 2, pp 284–292 | Cite as

Biopolymer-Based Transdermal Films of Donepezil as an Alternative Delivery Approach in Alzheimer’s Disease Treatment

  • Maviye Galipoğlu
  • Meryem Sedef Erdal
  • Sevgi Güngör
Research Article

Abstract

Matrix type transdermal films of donepezil (DNP) as an alternative delivery approach was designed to improve patient compliance to Alzheimer disease treatment. Sodium alginate, a natural polysaccharide, was used as matrix-forming agent in the optimization of transdermal films. Propylene glycol and dl-limonene was added into films as a plasticizer and permeation enhancer, respectively. As well as mechanical strength and bioadhesiveness of optimized transdermal films of DNP, the impact of dl-limonene concentration in films on DNP in vitro permeation across pig skin was assessed. Attenuated total reflectance-Fourier transform infrared (ATR-FTIR) measurements were carried out to examine the effects of enhancer on in vitro conformational order of the stratum corneum intercellular lipids following permeation study. Results showed that transdermal formulations of DNP were suitable due to both mechanical and bioadhesive features of the films. In vitro skin permeation study indicated that dl-limonene at a concentration of 3% was optimum with high drug flux. ATR-FTIR results confirmed a more fluidized stratum corneum lipid state in the presence of dl-limonene, indicating its permeation enhancement effect. Regarding to achieve therapeutic levels of DNP, it seems to be feasible deliver DNP with transdermal films for the management of Alzheimer disease.

KEY WORDS

Alzheimer disease donepezil limonene permeation enhancement transdermal film 

Notes

Conflicts of Interest

The authors declare no conflict of interest.

REFERENCES

  1. 1.
    Huang L, Su T, Li X. Natural products as sources of new lead compounds for the treatment of Alzheimer’s disease. Curr Top Med Chem. 2013;13(15):1864–78.CrossRefPubMedGoogle Scholar
  2. 2.
    Anand P, Singh B. A review on cholinesterase inhibitors for Alzheimer’s disease. Arch Pharm Res. 2013;36(4):375–99.CrossRefPubMedGoogle Scholar
  3. 3.
    Seltzer B. Donepezil: an update. Expert Opin Pharmacother. 2007;8(7):1011–23.CrossRefPubMedGoogle Scholar
  4. 4.
    Tsuno N. Donepezil in the treatment of patients with Alzheimer’s disease. Expert Rev Neurother. 2009;9(5):591–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Stefano AD, Iannitelli A, Laserra S, Sozio P. Drug delivery strategies for Alzheimer’s disease treatment. Expert Opin Drug Deliv. 2011;8(5):581–603.CrossRefPubMedGoogle Scholar
  6. 6.
    Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261–8.CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.
    Guy RH, Hadgraft J. Transdermal drug delivery. 2nd ed. New York: Marcel Dekker Inc; 2002.Google Scholar
  8. 8.
    Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2012;64:128–37.CrossRefGoogle Scholar
  9. 9.
    Fox LT, Gerber M, Du Plesis J, Hamman JH. Transdermal drug delivery enhancement by compounds of natural origin. Molecules. 2011;16:10507–40.CrossRefGoogle Scholar
  10. 10.
    Gao S, Singh J. In vitro percutaneous absorption enhancement of a lipophilic drug tamoxifen by terpenes. J Control Rel. 1998;51:193–9.CrossRefGoogle Scholar
  11. 11.
    Sapra B, Jain S, Tiwary AK. Percutaneous permeation enhancement by terpenes: mechanistic view. AAPS J. 2008;10(1):120–32.CrossRefPubMedCentralPubMedGoogle Scholar
  12. 12.
    Sakeena MH, Elrashid SM, Muthanna FA, Ghassan ZA, Kanakal MM, Laila L, et al. Effect of limonene on permeation enhancement of ketoprofen in palm oil esters nanoemulsion. J Oleo Sci. 2010;59(7):395–400.CrossRefPubMedGoogle Scholar
  13. 13.
    Krishnaiah YS, Raju V, Shiva Kumar M, Rama B, Raghumurthy V, Ramana Murthy KV. Studies on optimizing in vitro transdermal permeation of ondansetron hydrochloride using nerodilol, carvone, and limonene as penetration enhancers. Pharm Dev Technol. 2008;13(3):177–85.CrossRefPubMedGoogle Scholar
  14. 14.
    Labarre DJP, Ponchel G, Vauthier C. Biomedical and pharmaceutical polymers. 1st ed. London: Pharmaceutical Press; 2011.Google Scholar
  15. 15.
    Rowe RC, Sheskey PJ, Quinn ME. Handbook of pharmaceutical excipients. 6th ed. London: Pharmaceutical Press; 2009.Google Scholar
  16. 16.
    Aktar B, Erdal MS, Sagirli O, Güngör S, Özsoy Y. Optimization of biopolymer based transdermal films of metoclopramide as an alternative delivery approach. Polymers. 2014;6:1350–65.CrossRefGoogle Scholar
  17. 17.
    Bektaş A, Cevher E, Güngör S, Özsoy Y. Design and evaluation of polysaccharide-based transdermal films for the controlled delivery of nifedipine. Chem Pharm Bull. 2014;62(2):144–52.Google Scholar
  18. 18.
    Silva CL, Pereira JC, Ramalho A, Pais AC, Sousa JJS. Films based on chitosan polyelectrolyte complexes for skin drug delivery: development and characterization. J Membr Sci. 2008;320:268–79.CrossRefGoogle Scholar
  19. 19.
    Can AS, Erdal MS, Güngör S, Özsoy Y. Optimization and characterization of chitosan films for transdermal delivery of ondansetron. Molecules. 2013;18:5455–71.CrossRefPubMedGoogle Scholar
  20. 20.
    Hathout RM, Elshafeey AH. Development and characterization of colloidal soft nano-carriers for transdermal delivery and bioavailability enhancement of an angiotensin II receptor blocker. Eur J Pharm Biopharm. 2012;82(2):230–40.CrossRefPubMedGoogle Scholar
  21. 21.
    Li T, Ren C, Wang M, Zhao L, Wang X, Fang L. Optimized preparation and evaluation of indomethacine transdermal patch. Asian J Pharm. 2007;2:249–59.Google Scholar
  22. 22.
    Nair AB, Kumria R, Harsha S, Attimarad M, Al-Dhubiab BE, Alhaider IA. In vitro techniques to evaluate buccal films. J Control Rel. 2013;166:10–21.CrossRefGoogle Scholar
  23. 23.
    Güngör S, Erdal MS, Özsoy Y. Plasticizers in transdermal drug delivery systems. In Mohammad Luqman, editor. Recent advances in plasticizers. Rijeka: Intech;2012.p. 91–112.Google Scholar
  24. 24.
    Nesseem DI, Eid SF, El-Houseny SS. Development of novel transdermal self-adhesive films for tenoxicam, an anti-inflammatory drug. Life Sci. 2011;89:430–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Gutschke E, Bracht S, Nagel S, Weitschies W. Adhesion testing of transdermal matrix patches with a probe tack test, in vitro and in vivo evaluation. Eur J Pharm Biopharm. 2010;75:399–404.CrossRefPubMedGoogle Scholar
  26. 26.
    Rizwan M, Aqil M, Ahad A, Sultana Y, Ali MM. Transdermal delivery of valsartan: I. Effect of various terpenes. Drug Dev Ind Pharm. 2008;34:618–26.CrossRefPubMedGoogle Scholar
  27. 27.
    Godin B, Touitou E. Transdermal skin delivery: predictions for humans from in vivo, ex vivo and animal models. Adv Drug Del Rev. 2007;59:1152–61.CrossRefGoogle Scholar
  28. 28.
    Femenia-Font A, Balaguer-Fernandez C, Merino V, Rodilla V, Lopez-Castellano A. Effect of chemical enhancers on the in vitro percutaneous absorption of sumatriptan succinate. Eur J Pharm Biopharm. 2005;61:50–5.CrossRefPubMedGoogle Scholar
  29. 29.
    Vaddi HK, Ho PC, Chan YW, Chan SY. Terpenes in ethanol: haloperidol permeation and partition through human skin and stratum corneum changes. J Control Rel. 2002;81:121–33.Google Scholar
  30. 30.
    Padula C, Nicoli S, Colombo P, Santi P. Single-layer transdermal film containing lidocaine: modulation of drug release. Eur J Pharm Biopharm. 2010;66:422–8.CrossRefGoogle Scholar
  31. 31.
    Benson HAE. Transdermal drug delivery: penetration enhancement techniques. Curr Drug Deliv. 2005;2:23–33.CrossRefPubMedGoogle Scholar
  32. 32.
    Naik A, Kalia YN, Guy RH. Transdermal drug delivery: overcoming the skin’s barrier function. Pharm Sci Technol Today. 2000;3:318–26.CrossRefPubMedGoogle Scholar
  33. 33.
    Lim PF, Liu XY, Kang L, Ho PC, Chan YW, Chan SY. Limonene GP1/PG organogel as a vehicle in transdermal delivery of haloperidol. Int J Pharm. 2006;311(1–2):157–64.CrossRefPubMedGoogle Scholar
  34. 34.
    Cornwell PA, Barry BW. The routes of penetration of ions and 5-fluorouracil across human skin and the mechanisms of action of terpene skin penetration enhancers. Int J Pharm. 1993;94:189–94.CrossRefGoogle Scholar
  35. 35.
    İbrahim SA, Li KS. Chemical enhancer solubility in human stratum corneum lipids and enhancer mechanism of action on stratum corneum lipid domain. Int J Pharm. 2010;383:89–98.CrossRefPubMedCentralPubMedGoogle Scholar
  36. 36.
    Paduch R, Kandefer-Szerszen M, Trytek M, Fiedurek J. Terpenes: substances useful in human health care. Arch Immunol Ther Exp. 2007;55:315–27.CrossRefGoogle Scholar
  37. 37.
    Fang JY, Hwang TL, Leu YL. Effect of enhancers and retarders on percutaneous absorption of flurbiprofen from hydrogels. Int J Pharm. 2003;250:313–25.CrossRefPubMedGoogle Scholar
  38. 38.
    Anjos JL, Alonso A. Terpenes increase the partitioning and molecular dynamics of an amphipathic spin label in stratum corneum membranes. Int J Pharm. 2008;350(1–2):103–12.CrossRefPubMedGoogle Scholar
  39. 39.
    Yang Z, Teng Y, Wang H, Hou H. Enhancement of skin permeation of bufalin by limonene via reservoir type transdermal patch: formulation design and biopharmaceutical evaluation. Int J Pharm. 2013;447:231–40.CrossRefPubMedGoogle Scholar
  40. 40.
    Gorcea M, Hadgraft J, Moore DJ, Lane ME. In vivo barrier challenge and initial recovery in human facial skin. Skin Res Technol. 2013;19:375–82.CrossRefGoogle Scholar
  41. 41.
    Laugel C, Yagoubi N, Baillet A. ATR-FTIR spectroscopy: a chemometric approach for studying the lipid organization of the stratum corneum. Chem Phys Lipids. 2005;135:55–68.CrossRefPubMedGoogle Scholar
  42. 42.
    Moghimi HR, Makhmalzadeh BS, Manafi A. Enhancement effect of terpenes on silver sulphadiazine permeation through third-degree burn eschar. Burns. 2009;35:1165–70.CrossRefPubMedGoogle Scholar
  43. 43.
    Sozio P, Cerasa LS, Marinelli L, Stefano AD. Transdermal donepezil on the treatment of Alzheimer’s disease. Neuropsychiatr Dis Treat. 2012;8:361–8.PubMedCentralPubMedGoogle Scholar
  44. 44.
    Choi J, Choi MK, Chong S, Chung SJ, Shim CK, Kim DD. Effect of fatty acids on the transdermal delivery of donepezil: in vitro and in vivo evaluation. Int J Pharm. 2012;422:83–90.CrossRefPubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2014

Authors and Affiliations

  • Maviye Galipoğlu
    • 1
  • Meryem Sedef Erdal
    • 1
  • Sevgi Güngör
    • 1
  1. 1.Faculty of Pharmacy, Department of Pharmaceutical TechnologyIstanbul UniversityIstanbulTurkey

Personalised recommendations